1. Home
  2. KRYS vs FHI Comparison

KRYS vs FHI Comparison

Compare KRYS & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$244.20

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Federated Hermes Inc.

FHI

Federated Hermes Inc.

HOLD

Current Price

$52.03

Market Cap

4.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRYS
FHI
Founded
2015
1955
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
4.0B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
KRYS
FHI
Price
$244.20
$52.03
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$214.22
$49.00
AVG Volume (30 Days)
277.7K
598.3K
Earning Date
11-03-2025
01-29-2026
Dividend Yield
N/A
2.62%
EPS Growth
275.72
50.93
EPS
6.66
4.77
Revenue
$373,164,000.00
$1,742,513,000.00
Revenue This Year
$36.14
$10.23
Revenue Next Year
$41.80
$6.95
P/E Ratio
$36.79
$10.89
Revenue Growth
54.51
8.98
52 Week Low
$122.80
$35.05
52 Week High
$248.60
$54.42

Technical Indicators

Market Signals
Indicator
KRYS
FHI
Relative Strength Index (RSI) 81.72 63.16
Support Level $213.83 $50.01
Resistance Level $241.65 $51.42
Average True Range (ATR) 7.53 0.95
MACD 2.17 0.33
Stochastic Oscillator 89.34 83.65

Price Performance

Historical Comparison
KRYS
FHI

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About FHI Federated Hermes Inc.

Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).

Share on Social Networks: